BioAge Labs Inc. (BIOA) Cash Flow Statement

The OCF/NI ratio has oscillated between 0.24 and 1.34 over the period shown, but this variability appears driven more by working capital timing and the rising non-cash SBC add-back than by any improvement in earnings quality. Because SBC itself represents real economic cost via dilution, the fact that the cash loss (-$19.3M) still closely tracks the reported loss (-$26.1M) suggests BIOA has limited accrual cushion to lean on; investors should treat the burn rate as roughly equivalent to the reported operating deficit once SBC is re-priced as an economic expense.

The apparent improvement in FCF margin to -8.0% in Q2 2026 from -12.3% in Q1 2025 may look encouraging, but the data suggests this reflects revenue entering the denominator rather than burn reduction, since absolute outflow grew from -$17.8M to -$19.6M over that span. The burn also proved non-linear, dipping to -$16.1M in Q3 2025 before re-accelerating to -$28.4M in Q4 2025 and remaining near -$20M thereafter, a pattern consistent with the escalating R&D spending identified in the income statement analysis and implying the cost base has re-set at a structurally higher level.

The magnitude of these swings, including a -$7.5M reversal in Q1 2025 following the Q4 2024 inflow, suggests cash movements are being dictated by the timing of milestone payments or large single-counterparty settlements rather than a predictable operating cycle, which is typical for pre-commercial biotech but complicates forecasting. The +$2.8M contribution in the latest quarter therefore warrants scrutiny before being extrapolated; if it reflects one-time receipt timing, the more representative burn figure is closer to the -$22M implied by Q1 2026 rather than the -$19.6M headline.

The near-absence of CapEx, which cumulatively totals roughly $1.7M against approximately -$177M of operating outflow, confirms BIOA operates an asset-light model where cash deployment is overwhelmingly an R&D decision rather than a manufacturing or infrastructure one. This provides flexibility, as no committed capital programs appear to be constraining the cash position, but it also means there is no tangible asset base to show for the ~$178M of cumulative FCF consumed, placing total reliance on clinical or partnership outcomes for value realization.

The absence of a larger cumulative divergence between earnings and cash flow implies BIOA has limited non-cash charges beyond SBC to absorb its losses, distinguishing it from asset-heavy peers where depreciation might meaningfully separate accounting loss from cash drain. The practical implication is that the ~$24M of cumulative divergence should not be read as hidden cash generation; it represents SBC that has been paid back out in equity, meaning the economic cost of operations is arguably wider than either the reported loss or the cash outflow alone suggests.